Approximately 20% of shoe allergens are not detected with the current screening series, according to a retrospective study of more than 30,000 patients. Contact allergy to shoes remains a common but difficult...

Ruxolitinib cream, an investigational selective Janus kinase 1 and 2 inhibitor now under priority review by the Food and Drug Administration for the treatment of atopic dermatitis (AD) down to age 12 years,...